financetom
Business
financetom
/
Business
/
Puravankara achieves highest-ever sales in Q1, expects the trend to continue
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Puravankara achieves highest-ever sales in Q1, expects the trend to continue
Aug 14, 2023 10:53 AM

Puravankara recorded its highest-ever sales value in a quarter at around Rs 1,100 crore and the company expects this trend to continue. Speaking to CNBC-TV18, Abhishek Kapoor, Group CEO of the company highlighted this as a crucial factor contributing to their exceptional growth.

He said, “This is the first year as an organisation, we have beaten our Q4 number in a leaner quarter. And of course, reflective of the fact that we have done 119 percent growth on a year-on-year basis is clearly the fact is that the business is performing.”

Kapoor confidently affirmed, “We are expecting to continue the same trend. We are launching more projects in this quarter and the next quarter.”

The CEO further elaborated on the company's future plans, revealing an impressive lineup of projects. He revealed, "During the year, we have about 16 billion square foot of total launch developable area. Our share of it, developer's share of it is about 13 million."

One of the noteworthy aspects of Puravankara's recent success is the improved performance of their sustenance projects. Kapoor highlighted this as a crucial factor contributing to their exceptional growth.

When discussing the financial aspects of the company's operations, Kapoor highlighted Puravankara's commitment to managing its debt effectively. "From the debt point of view, we are consistently at similar levels, we intend to keep it at similar levels," he explained.

Kapoor also acknowledged the need for capital infusion in new acquisitions, which is an integral part of Puravankara's growth strategy. He stated, "While we repay debt, there will also be capital required for new acquisitions, and therefore the debt numbers will remain the same."

Watch the accompanying video for more

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Provident Healthcare Partners Advises A Caring Experience Nursing Services, Inc. on its Acquisition by HouseWorks Holdings, LLC, a Portfolio Company of InTandem Capital Partners
Provident Healthcare Partners Advises A Caring Experience Nursing Services, Inc. on its Acquisition by HouseWorks Holdings, LLC, a Portfolio Company of InTandem Capital Partners
Mar 11, 2026
BOSTON, March 11, 2026 /PRNewswire/ -- Provident Healthcare Partners (Provident), a leading healthcare investment banking firm, announced it has advised A Caring Experience Nursing Services, Inc. (ACE), a Cranston, Rhode Island-based provider of in-home care services, on its partnership with HouseWorks Holdings, LLC (HouseWorks), one of the nation's leading personal care services companies. The acquisition expands HouseWorks' footprint in New...
US DOJ says Aetna to pay $117.7 million to resolve False Claims Act allegations
US DOJ says Aetna to pay $117.7 million to resolve False Claims Act allegations
Mar 11, 2026
WASHINGTON, March 11 (Reuters) - The U.S. Justice Department said on Wednesday that CVS Health's ( CVS ) Aetna agreed to pay $117.7 million to resolve allegations that it violated the False Claims Act. ...
Navitas Semiconductor Stock Soars After New Product Launch
Navitas Semiconductor Stock Soars After New Product Launch
Mar 11, 2026
Navitas Semiconductor Corp ( NVTS ) shares are trading higher Wednesday morning after the company unveiled two new additions to its 5th generation GeneSiC silicon carbide power semiconductor platform, highlighting its push into AI data centers and energy infrastructure. Here’s what investors need to know. Navitas Semiconductor ( NVTS ) stock is among today’s top performers. What’s fueling NVTS momentum?...
Regenxbio's Duchenne gene therapy shows improved muscle function in trial
Regenxbio's Duchenne gene therapy shows improved muscle function in trial
Mar 11, 2026
March 11 (Reuters) - Regenxbio ( RGNX ) said on Wednesday that an interim data from a early-to-mid stage study of its experimental gene therapy in patients with Duchenne muscular dystrophy showed continued improvement in muscle function and a clean safety profile. (Reporting by Kamal Choudhury in Bengaluru) ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved